131I-tositumomab radioimmunotherapy: Initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling

Journal of Nuclear Medicine

Volumn 51, Issue 7, 2010, Pages 1155-1162

  Dewaraja, Yuni K ^a   Schipper, Matthew J ^b   Roberson, Peter L ^b   Wilderman, Scott J ^a   Amro, Hanan ^b   Regan, Denise D ^a   Koral, Kenneth F ^a   Kaminski, Mark S ^a   Avram, Anca M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Dose response; Patient specific dosimetry; Radiobiology; Radioimmunotherapy; SPECT CT

Indexed keywords

TOSITUMOMAB; TOSITUMOMAB I 131; ANTINEOPLASTIC AGENT; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ALGORITHM; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; CORRELATION ANALYSIS; DOSE RESPONSE; DOSIMETRY; EQUIVALENT UNIFORM DOSE; FEMALE; HUMAN; IMAGE DISPLAY; IMAGE RECONSTRUCTION; MALE; MODEL; MONTE CARLO METHOD; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR REGRESSION; BIOLOGICAL MODEL; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFECT; METHODOLOGY; NEOPLASM; RADIATION RESPONSE; RADIOMETRY; STATISTICS;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77954989427     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.075176     Document Type: Article

References (25)

1. Stabin M. Nuclear medicine dosimetry. Phys Med Biol. 2006;51:R187-R202.
2. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
3. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323.
4. DeNardo GL, DeNardo SJ, Shen S, et al. Factors affecting 131-I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Nucl Med. 1999;40:1317-1326.
5. 131I-tositumomab therapy of previouslyuntreated lymphoma patients. J Nucl Med. 2003;44:457-464.
6. 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44:260-268.
7. 90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med. 2003;44:2000-2018.
8. O'Donoghue JA. Implications of non-uniform tumor dose for radioimmunotherapy. J Nucl Med. 1999;40:1337-1341.
9. Hindorf C, Linden O, Stenberg L, Tennvall J, Strand SE. Change in tumor absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients. Clin Cancer Res. 2003;9:4003s-4006s.
10. Hartmann Siantar CL. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy. J Nucl Med. 2003;44:1322-1329.
11. Dewaraja YK, Wilderman SJ, Koral KF, Kaminski M, Avram AM. Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study. Cancer Biother Radiopharm. 2009;24:417-426.
12. Amro H, Wilderman SJ, Dewaraja YK, Roberson PL. Methodology to incorporate biologically effective dose and equivalent uniform dose in patientspecific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy. J Nucl Med. 2010;51:654-659.
13. Dewaraja YK, Ljungberg M, Koral KF. Effects of dead time and pile up on quantitative SPECT for I-131 dosimetric studies [abstract]. J Nucl Med. 2008;49(suppl):47P.
14. Koral KF, Yendiki A. Qiang Lin, Dewaraja YK. Comparison of 3-D OSEM versus 1-D SAGE for focal total-activity quantification in I-131 SPECT with HE collimation. IEEE Trans Nucl Sci. 2005;52:154-158.
15. Dewaraja YK, Wilderman SJ, Ljungberg M, Koral KF, Zasadny K, Kaminiski M. Accurate dosimetry in I-131 radionuclide therapy using patient specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med. 2005;46:840-849.
16. Dewaraja YK, Avram AM, Schipper M, et al. Quantitative SPECT/CT for radioimmunotherapy (RIT) treatment planning: comparison of tracer and therapy dosimetry [abstract]. J Nucl Med. 2009;50(suppl):98P.
17. Pinheiro JC, Bates DM. Approximations to the log-likelihood function in the nonlinear mixed-effects model. J Comput Graph Statist. 1995;4:12-35.
18. Wilderman SJ, Dewaraja YK. Method for fast CT/SPECT based 3D Monte Carlo absorbed dose computations in internal emitter therapy. IEEE Trans Nucl Sci. 2007;54:146-151.
19. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
20. Davis TA, Kaminski M, Leonard J, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004;10:7792-7798.
21. Sgouros G. Dosimetry of internal emitters. J Nucl Med. 2005;46(suppl):18S-27S.
22. Brans B, Bodei L, Giammarile F et al. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray." Eur J Nucl Med Mol Imaging. 2007;34:772-786.
23. 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46(suppl):92S-98S. (Pubitemid 47619024)
24. 131I-MIBG. J Nucl Med. 2001;42:1713-1721.
25. Koral KF, Yendiki A, Dewaraja YK. Recovery of I-131 activity within focal volumes using SPECT and 3D OSEM. Phys Med Biol. 2007;52:777-790.